DE602004026474D1 - Rekombinanter faktor viii mit erhöhter spezifischer aktivität - Google Patents

Rekombinanter faktor viii mit erhöhter spezifischer aktivität

Info

Publication number
DE602004026474D1
DE602004026474D1 DE602004026474T DE602004026474T DE602004026474D1 DE 602004026474 D1 DE602004026474 D1 DE 602004026474D1 DE 602004026474 T DE602004026474 T DE 602004026474T DE 602004026474 T DE602004026474 T DE 602004026474T DE 602004026474 D1 DE602004026474 D1 DE 602004026474D1
Authority
DE
Germany
Prior art keywords
factor viii
recombinant factor
specific activity
increased specific
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004026474T
Other languages
English (en)
Inventor
Philip J Fay
Hironao Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of DE602004026474D1 publication Critical patent/DE602004026474D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004026474T 2003-12-03 2004-12-02 Rekombinanter faktor viii mit erhöhter spezifischer aktivität Active DE602004026474D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52666403P 2003-12-03 2003-12-03
PCT/US2004/040234 WO2005055930A2 (en) 2003-12-03 2004-12-02 Recombinant factor viii having increased specific activity

Publications (1)

Publication Number Publication Date
DE602004026474D1 true DE602004026474D1 (de) 2010-05-20

Family

ID=34676640

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026474T Active DE602004026474D1 (de) 2003-12-03 2004-12-02 Rekombinanter faktor viii mit erhöhter spezifischer aktivität

Country Status (7)

Country Link
US (1) US7855274B2 (de)
EP (1) EP1699469B1 (de)
AT (1) ATE463572T1 (de)
AU (1) AU2004296768B2 (de)
CA (1) CA2547569C (de)
DE (1) DE602004026474D1 (de)
WO (1) WO2005055930A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371856B1 (de) 2004-11-12 2022-05-18 Bayer HealthCare LLC Ortsgerichtete Modifizierung von FVIII
CA2615328A1 (en) 2005-07-15 2007-01-25 The University Of Vermont And State Agriculture College Highly sensitive immunoassays and antibodies for detection of blood factor viii
EP1996465A2 (de) 2006-03-10 2008-12-03 Goodrich Corporation Schutz vor blitzschlägen von geringer dichte zur verwendung in flugzeugen
RU2531493C2 (ru) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Рекомбинантный фактор viii, обладающий повышенной стабильностью
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
LT3013855T (lt) * 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
WO2017180857A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN111651033B (zh) * 2019-06-26 2024-03-05 广州虎牙科技有限公司 一种人脸的驱动显示方法、装置、电子设备和存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
AU2001292861A1 (en) 2000-09-19 2002-04-02 Emory University Modified factor VIII
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
EP2110385A1 (de) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilisierte Faktor VIII mit manipulierten Disulfid-Bindungen
EP1424344A1 (de) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte cDNA des Factors VIII und Derivate davon
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Also Published As

Publication number Publication date
AU2004296768A1 (en) 2005-06-23
EP1699469B1 (de) 2010-04-07
AU2004296768B2 (en) 2010-06-24
US7855274B2 (en) 2010-12-21
ATE463572T1 (de) 2010-04-15
EP1699469A2 (de) 2006-09-13
CA2547569C (en) 2013-04-16
WO2005055930A3 (en) 2005-08-18
EP1699469A4 (de) 2007-01-24
CA2547569A1 (en) 2005-06-23
WO2005055930A2 (en) 2005-06-23
US20070265199A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
NO20042570L (no) Antimikrobielle polypeptider fra Pseudoplectania nigrella
ATE492633T1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
MX2007007862A (es) Proteasas fungales acidas.
WO2003000941A3 (en) Polypeptides having cellobiohydrolase i activity and polynucleotides encoding same
DK1266011T3 (da) Svampetranskriptionsaktivator, der er anvendelig i fremgangsmåder til fremstilling af polypeptider
WO2002095014A3 (en) Polypeptides having cellobiase activity and polynucleotides encoding same
ATE438711T1 (de) Polypeptide mit cellobiohydrolase ii-aktivität und dafür kodierende polynucleotide
EP2857515A3 (de) Polypeptide mit verstärkter amylolytischer Aktivität und Polynukleotide zur Codierung davon
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
EP2284184A3 (de) Bacillus YvmA-Deaktivierung
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
EA201070764A1 (ru) Полипептиды, обладающие активностью, усиливающей лизис целлюлозы, и кодирующие их полинуклеотиды
ATE533839T1 (de) Phytasenvarianten
ATE513907T1 (de) Polypeptide mit endoglucanase-aktivität und polynukleotide zu ihrer kodierung
EA200901110A1 (ru) Рекомбинантная клетка-хозяин для получения соединения, представляющего интерес
DE602004021836D1 (de) Meg1-endospermspezifische promotoren und gene
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
ATE463572T1 (de) Rekombinanter faktor viii mit erhöhter spezifischer aktivität
EA200700233A1 (ru) Новая последовательность для повышения экспрессии нуклеиновой кислоты
DK1877551T3 (da) Polypeptider, der har endoglucanaseaktivitet, og polynukleotider, der koder for samme
DK1117798T3 (da) Fungal transskriptionel aktivator egnet ved fremgangsmåder til produktion af polypeptider
WO2003106674A3 (en) MEANS AND METHODS FOR REGULATING GENE EXPRESSION
DK0981631T3 (da) Polypeptider, som har aminopeptidase-aktivitet, og nukleinsyrer, som koder for samme
NO20034692L (no) Nye polynukleotider og polypeptider av INF gamma-17 genet
ATE542913T1 (de) Promotorvarianten zur expression von genen in einer pilzzelle

Legal Events

Date Code Title Description
8364 No opposition during term of opposition